TP, TS AND DPD as Potential Predictors of Outcome Following Capecitabine Plus Oxaliplatin (XELOX) vs. Bolus 5-Fluorouracil/Leucovorin (5-FU/LV) as Adjuvant Therapy for Stage III Colon Cancer: Updated Biomarker Findings from Study NO16968 (XELOXA) | Publicación